Stephen Wiggins, our Chairman and Chief Executive Officer , has over 30 years of experience founding, launching and managing health care companies including Oxford Health Plans, which grew into a Fortune 500 company under his leadership. His businesses span information technology, advanced analytics, health insurance and specialty pharmaceuticals. Mr. Wiggins is currently a private investor, operating his solely-owned investment vehicles, Wiggins Ventures, Inc. and Wiggins Holdings LLC. He has served as the Managing Member of Butlers Islands LLC, an investment holding company, since 2015. He previously served as the Chairman of Remedy Partners (“Remedy”) from September 2011 to December 2019. Mr. Wiggins founded Remedy and led it to becoming the largest company in the growing field of health care bundled payments, in which insurers make a fixed payment for a patient’s entire episode of care. Remedy has partnerships with health care organizations across the U.S. managing over $6 billion of annual health care spending. In December 2019, Remedy merged with Signify Health, Inc. (NYSE: SGFY) and Mr. Wiggins has continued to serve as a Director of Signify. He served as the Chairman of the Board of Smokenders, Inc., a company that provides comprehensive smoking cessation programs, from its acquisition by Oxford Health Plans in the 1990s until his departure from Oxford Health Plans in around 1998. From March 2008 to January 2018, Mr. Wiggins served as a Managing Director of EW Healthcare Partners (“EW”), a global health care private equity firm, where he led the Services and Information Technology practice and served on the Investment Committee, and in connection with this role, he also served as an executive officer of multiple related holding companies since 2009, including Essex Woodlands Management, Inc., Essex Woodlands Services Co., Inc., Essex Woodlands Special Situation Partners, LLC, Essex Woodlands Health Ventures VIII, LLC and Essex Woodlands IX, LLC. EW manages over $3 billion of investments in all sectors of the health care industry. Mr. Wiggins founded and served as the member of the Centerstone Partners (formerly known as the FMR Group), an investment holding company, from March 2008 to February 2018. From October 1999 to June 2004, Mr. Wiggins served as Chairman and Chief Executive Officer of HealthMarket, Inc., an insurance company that Mr. Wiggins founded that developed the innovative Consumer Driven Health Plans. He also co-founded Health Partners in 1994, a physician practice management company, and Intelliclaim, Inc. in 1998, a company providing software and services to health insurance companies. Each of these companies was ultimately acquired by companies in the health care industry. Mr. Wiggins is a Director of Accessible Space, a non-profit organization he founded in 1978, which operates residential facilities for individuals with mobility impairments and brain injuries, and in connection with this role, he also served as the Director of multiple related holding companies since 2009, including ASI – Las Vegas, Inc., ASI-Reno, Inc., ASI Carson City, Inc. and ASI Helena, Inc. Since 1997, Mr. Wiggins has been involved in a series of class action lawsuits owing to alleged securities violations on the part of Oxford Health Plans’ principals, including himself. The alleged securities violations included significant overstatements of Oxford Health Plan’s profits, causing shares of Oxford Health Plans to dramatically decrease in value and causing its “financial collapse.” As a result, Mr. Wiggins resigned in exchange for an injection of funds from Texas Pacific Group. These actions were all consolidated under a multi-district litigation docket. In March 2003, Oxford Health Plans agreed to settle this litigation for $225 million and the consolidated litigation was terminated on June 12, 2003. In addition, in December 1997, while he was the Chief Executive Officer, Oxford Health Plans was also fined approximately $3 million by the New York State Insurance Department (the “NYSID”). The NYSID found that Oxford Health Plans had violated unspecified New York state insurance regulations and described the “poor planning and/or inexperienced management” as the apparent cause of many of its difficulties and catalogued numerous regulatory infractions by Oxford Health Plans, including raising customers’ premiums without sufficient notice. Mr. Wiggins graduated from Macalester College and has a Master of Business Administration degree from Harvard Business School. We believe Mr. Wiggins is well qualified to serve as one of our directors due to his extensive experience in launching, managing and growing healthcare companies.

James Cardwell, our Chief Financial Officer , has over 15 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance. He has served as the Chief Operating Officer of the CFO Squad LLC, an accounting firm, since July 2015. In connection with his role at the CFO Squad LLC, he also served as interim Chief Financial Officer at several entities, including NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company, from June 2019 to October 2020; Esports Entertainment Group (NASDAQ: GMBL), an esports and online gambling company, from February 2020 to June 2020; Stemtech Corporation, a nutrition supplement company, since May 2020; NewGioco Group Inc., a gaming technology company, from August 2018 to December 2018; and VerifyMe Inc., a company that provides comprehensive brand protection and customer engagement solutions, from January 2018 to May 2018. Mr. Cardwell served as the Chief Financial Officer of S2BN Entertainment Corporation, a New York-based entertainment producer and promoter, from 2011 to 2015. He served as the Chief Financial Officer and Chief Operating Officer of Sibling Entertainment, Inc. (OTCQB: SIBE), an innovative education company, from 2002 to 2010. Mr. Cardwell started his public accounting career at Arthur Andersen & Co. (St. Louis) and worked as a Tax Accountant from 1981 to 1985, with clients including General Dynamics, Anheuser-Bush, May Department Stores and others. Mr. Cardwell has extensive experience in corporate structure, financial reporting and modeling, mergers and acquisition, quality of earnings and business analysis, SEC reporting, tax and compliance. He currently serves as the Trustee of Jun Street United Methodist Church and John Street Trust Fund Society. He is also the Treasurer and Director of Southold Historical Society. Mr. Cardwell has a Bachelor of Science degree in Accounting at the Illinois State University. We believe Mr. Cardwell is well qualified to serve as our Chief Financial Officer due to his extensive experience in corporate structure, financial reporting and modeling, mergers and acquisition, quality of earnings and business analysis, SEC reporting, tax and compliance.

Joseph Nelson, our Chief Operating Officer , is a seasoned entrepreneur, business executive and investor with 20 years of experience establishing and operating companies in diverse industries including information technology, medical devices, predictive analytics and energy trading. He has an extensive background in management, strategic planning, fundraising and administration. Mr. Nelson is currently a private investor. Most recently, he was involved in the North American wholesale electricity market where he founded and acted as Managing Member of Blue Lantern Capital LLC (“Blue Lantern”), a boutique algorithmic energy trading company, from December 2015 to January 2020. Blue Lantern’s proprietary software helped promote the efficient convergence of wholesale power pricing, ultimately reducing costs for rate-paying electricity consumers. Blue Lantern was sold in January 2020. Mr. Nelson previously formed Syntergy LLC (“Syntergy”), a medical device company and served as its managing member from July 2010 to December 2012. Syntergy sold a surgical adhesive that replaced sutures in emergency departments and operating rooms. Syntergy was sold in 2012. Mr. Nelson is a scientist by training and graduated from Bob Jones University with a Bachelor of Science degree in Pre-Med/Chemistry. He attended graduate school at American University with a focus on bio-analytical chemistry. We believe Mr. Nelson is well qualified to serve as our Chief Operating Officer due to his outstanding track record of establishing and operating companies in diverse industries and solid background in management, strategic planning, fundraising and administration.

William J. Febbo, who will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part, has led health service, technology and finance companies for the past 20 years, connecting key participants in the healthcare industry and launching pioneering digital compliance and transparency products. Since February 2016, he has served as the Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ: OPRX), including its subsidiaries, where he has led its transformation into a leading digital health company that facilitates communication at the point-of-care for better health outcomes. Since January 2020, Mr. Febbo has served as a member of the Board of Directors and Compensation Committee of Modular Medical Inc. (OTCMKTS: MODD), a development stage company engaging in the provision of insulin pump technology. He has also served as a director of Performance Health System, LLC, an international company specializing in developing health and wellness equipment, since May 2020 and the Managing Director of Tailwinds, LLC, a consulting company for board and strategic efforts, since January 2019. He previously served as a Director of PlenOptika, Inc., a company focusing on optical technology and devices, from October 2018 to April 2021, and Rx Redefined, a company operating online platforms for medical supplies, from January 2018 to December 2020. In 1999, Mr. Febbo co-founded and became the Chief Executive Officer of MedPanel Inc, a market intelligence and communication provider to the life sciences and financial industries. MedPanel was acquired in 2007 by Merriman Capital (“Merriam”), a leading investment bank. Mr. Febbo continued with Merriman, where he served as the Chief Operating Officer of investment banking and the Chief Executive Officer of the firm’s Digital Capital Network until 2015. Earlier in his career, Mr. Febbo held a number of M&A and international business development roles at multinational companies involved in automotive, medical, precious metals and other industries. He currently serves as a faculty member for Massachusetts Institute of Technology’s linQ program, a collaborative initiative increasing the potential of innovative biomedical research to benefit society and the economy. Mr. Febbo serves on board of The United Nations of Greater Boston, a non-profit focused on building a stronger network of global citizens in the Boston area. Mr. Febbo earned his Bachelor of Arts degree in International Studies and Spanish from Dickinson College, Pennsylvania. In January 2018, without admitting or denying the findings of FINRA’s investigation, Mr. Febbo consented to an administrative sanction of $5,000 and a 10-day suspension of his capacity as a financial and operations principal, with reinstatement upon his requalification by examination for Series 27 license. Mr. Febbo allegedly failed to accurately compute Merriman’s net capital and failed to recognize that Merriman was maintaining net capital that was as much as $509,000 below its regulatory minimum net capital requirement. We believe Mr. Febbo is well qualified to serve as one of our directors due to his rich experience in leading healthcare services and technology companies and connections in the health-related industries.

Goran Ando, who will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part, has had a distinguished career in the global pharmaceutical industry that has spanned nearly four decades. He is a Senior Advisor at EW. Dr. Ando has served as Chairman of the Board for several U.S. and European-based biopharmaceutical companies, including: Nanexa AB (NANEXA: SS), a Swedish nanotechnology company, since June 2020; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), an American biopharmaceutical company, since September 2017; Nouscom AG, a Swiss immunotherapy company, since December 2020; Tessa Therapeutics Pre Ltd., a Singaporean clinical-stage biotechnology company, since May 2020; and Parexel, Inc., an American company providing biopharmaceutical services, since March 2018. Dr. Ando has served as a Director of Selecta Bioscience Inc. (NASDAQ: SELB), a clinical-stage biotechnology company, since April 2020, and a Director of Parexel International Corporation Ltd., a clinical research organization, since May 2018. He previously has also served as Chairman of the Board of Novo Nordisk A/S (NYSE: NVO) (“Novo Nordisk”), a Danish multinational pharmaceutical company, from April 2005 to April 2018, Molecular Partners AG (OTCMKTS: MLLCF), a Swiss biopharmaceutical company, from April 2010 to April 2020, and Symphogen A/S, a Danish biotechnology company, from June 2008 to December 2017. Dr. Ando served as Chief Executive Officer of Celltech Group plc., a British-based biotechnology company, from 2003 to 2005. He held various senior appointments at GlaxoSmithKline plc. (NYSE: GSK) from1989 to 1995, including Research and Development Director for Glaxo Group Research. In 1995, Dr. Ando joined Pharmacia AB as Executive Vice President and Deputy Chief Executive Officer to lead Research and Development with additional responsibilities for manufacturing, information technology, business development and M&A. During his eight-year tenure as Head of Research and Development at Pharmacia & Upjohn from1995 to 2003, 17 new drugs were approved by the U.S. Food and Drug Administration (the “FDA”). Pharmacia was acquired by Pfizer, Inc. in 2003. He qualified as a medical doctor at Linköping Medical University, Sweden, in 1973 and as a specialist in general medicine at the same institution in 1978. Dr. Ando is a founding fellow of the American College of Rheumatology in the U.S. Beginning in 2017 when Dr. Ando was the Chairman of the Board, Novo Nordisk was named a defendant in over 20 racketeer influenced and corrupt organization (“RICO”) lawsuits. Additionally, Novo Nordisk was also named a defendant in several securities lawsuits filed by shareholders who alleged that it had reported inflated earnings and financial projections due to the price-fixing scheme. The RICO lawsuits were consolidated into a single class-action lawsuit, and the securities lawsuits were consolidated into a single class-action lawsuit. Litigation in both class-action lawsuits is currently ongoing. Dr. Ando was not a party to any of the litigation. In September 2017, Novo Nordisk agreed to pay the Department of Justice $60 million to settle claims that it had downplayed the cancer risks of a diabetes medication that Novo Nordisk had developed. Dr. Ando was not named a party in such claims. We believe Dr. Ando is well qualified to serve as one of our directors due to his academic background in health and medical science and a distinguished career in the global pharmaceutical industry.

John Fitzpatrick, who will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part, has served as a non-executive director of American International Group (NYSE: AIG) since May 2011. Mr. Fitzpatrick has been Chairman of Oak Street Management Co., LLC, an insurance/management consulting company, and Oak Family Advisors, LLC, a registered investment advisor, since 2010. He was Chairman of White Oak Global Advisors LLC, an asset management firm lending to small and medium sized companies, from September 2015 to September 2017. In 2014, Mr. Fitzpatrick completed a two-year term as Secretary General and Managing Director of The Geneva Association, an international insurance think tank. From 2006 to 2010, he was a partner and director at Pension Insurance Corporation Ltd., a global pension management company. From 1998 to 2006, Mr. Fitzpatrick was a member of the Executive Board Committee of Swiss Reinsurance Company Ltd. (OTCMKTS: SSREF), a global reinsurance company based in Switzerland, and served at Swiss Re as its Chief Financial Officer, Head of the Life and Health Reinsurance Business Group and Head of Financial Services. From 1996 to 1998, Mr. Fitzpatrick was a partner in insurance-focused private equity firms sponsored by Zurich Financial Services, Credit Suisse and Swiss Re. Mr. Fitzpatrick started his career in 1978 at Kemper Corporation (NYSE: KMPR), an insurance and financial services company. Mr. Fitzpatrick is a Certified Public Accountant and a Chartered Financial Analyst. He graduated from Loyola University of Chicago with a Bachelor of Art degree in Accounting. We believe Mr. Fitzpatrick is well qualified to serve as one of our directors due to his extensive experience in the insurance and financial industries.

Adam Long, who will serve as one of our directors as of the effective date of the registration statement of which this prospectus forms a part, is an experienced investor in diverse industries including healthcare. He has partnered with numerous biotech, pharmaceutical, and specialty healthcare companies offering boutique investments to sector participants. Mr. Long has served as the managing member of Oasis Capital (“Oasis”) since April 2018. Oasis provides liquidity to early, middle and late-stage public and private companies, including in the healthcare industry. Prior to that, he served as the Managing Director of multiple private equity firms, including BMA Securities, Inc., from May 2015 to February 2016; Monarch Bay Securities LLC, from January 2014 to May 2015; Premonix, from June 2011 to December 2015; and Jera Securities, Inc., from December 2012 to January 2014. Mr. Long has also served as the President of Old Main Capital, a southern Florida based investment firm focused on small cap and microcap investments, since January 2015 and as Managing Member of L2 Capital, a Kansas based investment firm focused on small cap and microcap investments, since November 2016. Previously, Mr. Long worked in leadership or ownership roles as a broker/dealer and M&A advisor. Mr. Long graduated in 2003 from the University of Kansas with a Bachelor of Science in Business Administration with concentrations in Economics and Finance. We believe Mr. Long is well qualified to serve as one of our directors due to his rich experience in financial industry and capital markets as well as investing in the health-related industry.